If the trial succeeds, the vaccine could be the first human immunization for Lyme disease in the U.S. in two decades.
Berkeley Lovelace Jr.
There are currently no vaccines approved in the United States for the tick-borne illness, which infects an estimated 476,000 people in the U.S. each year, according to theIf Pfizer’s trial succeeds, the vaccine could be the first human inoculation available for Lyme disease in the U.S. in two decades. Only one other vaccine for the disease, LYMErix, has been used in the country, but it was discontinued in 2002.
The protein-based vaccine, called VLA15, is a three-dose regimen, administered over a five-to-nine month period, followed by a booster dose 12 months later. It targets Borrelia burgdorferi, the bacteria that cause Lyme disease. The company is developing the vaccine with French biotech firm Valneva.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Major test of first possible Lyme vaccine in 20 years beginsResearchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years
Baca lebih lajut »
Pfizer to buy South SF-based Global Blood Therapeutics in $5.4B dealPfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.
Baca lebih lajut »
Vaccine Targeting Fast-Spreading Omicron Subvariants Could Be Ready For Fall As Pfizer, BioNTech Announce TrialsPfizer and BioNTech will begin trials of their updated mRNA Covid-19 vaccine designed to protect against the newer BA.4 and BA.5 sub-variants of the coronavirus later this month.
Baca lebih lajut »
Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln dealPfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics , as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.
Baca lebih lajut »
Pfizer Agrees to $5.4 Billion Deal for Global Blood TherapeuticsPfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.
Baca lebih lajut »
Pfizer buying spree continues with $5.4B hematology dealPfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Baca lebih lajut »